SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hisashi Nishida, Etsuro Hatano, Koji Tomiyama, Satoshi Seo, Koujiro Taura, Yasuhiro Fujimoto, Masaki Mizumoto, Shinji Uemoto, A case of desensitization of sorafenib after tumor lysis syndrome and erythema multiform in the patient with advanced hepatocellular carcinoma, Kanzo, 2014, 55, 4, 221

    CrossRef

  2. 2
    Haruhiko Takeda, Hiroki Nishikawa, Yukio Osaki, Kaoru Tsuchiya, Kouji Joko, Chikara Ogawa, Hiroyoshi Taniguchi, Etsuro Orito, Yasushi Uchida, Namiki Izumi, Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan, Liver International, 2014, 34, 6
  3. 3
    Dalbir S. Sandhu, Esha Baichoo, Lewis R. Roberts, Fibroblast growth factor signaling in liver carcinogenesis, Hepatology, 2014, 59, 3
  4. 4
    Antoine Galmiche, Bruno Chauffert, Jean-Claude Barbare, New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma, Cancer Letters, 2014, 346, 2, 159

    CrossRef

  5. 5
    Henning Wege, Tim H. Brümmendorf, Carlo Gambacorti-Passerini, A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma, Hepatology, 2013, 57, 4
  6. 6
    Daisuke Miyaki, Hiroshi Aikata, Hiromi Kan, Hatsue Fujino, Ayako Urabe, Keiichi Masaki, Takayuki Fukuhara, Tomoki Kobayashi, Noriaki Naeshiro, Takashi Nakahara, Tomokazu Kawaoka, Akira Hiramatsu, Shoichi Takahashi, Masaki Ishikawa, Hideaki Kakizawa, Kazuo Awai, Kazuaki Chayama, Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy, Journal of Gastroenterology and Hepatology, 2013, 28, 12
  7. 7
    Roongruedee Chaiteerakij, Benyam D. Addissie, Lewis R. Roberts, Update on Biomarkers of Hepatocellular Carcinoma, Clinical Gastroenterology and Hepatology, 2013,

    CrossRef